The results suggested that tumor immune infiltration and tumor immune escape might be involved in COL1A2-medidated cancer development, providing clues for improving the immunotherapy efficacy of COAD by targeting COL1A2. This evidence concerns the gene COL1A2 and colon adenocarcinoma.